GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xintela AB (FRA:1XT) » Definitions » Other Gross PPE

Xintela AB (FRA:1XT) Other Gross PPE : €0.08 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xintela AB Other Gross PPE?

Xintela AB's Other Gross PPE for the quarter that ended in Sep. 2024 was €0.08 Mil.

Xintela AB's quarterly Other Gross PPE declined from Mar. 2024 (€0.11 Mil) to Jun. 2024 (€0.10 Mil) and declined from Jun. 2024 (€0.10 Mil) to Sep. 2024 (€0.08 Mil).


Xintela AB Other Gross PPE Historical Data

The historical data trend for Xintela AB's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xintela AB Other Gross PPE Chart

Xintela AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Xintela AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 - 0.11 0.10 0.08

Xintela AB Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Xintela AB Business Description

Traded in Other Exchanges
Address
Medicon Village, Lund, SWE, 22381
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.

Xintela AB Headlines

No Headlines